From Yahoo Finance: 2025-03-22 09:40:00

Scotiabank raised Alnylam’s price target to $338 from $300, maintaining an Outperform rating. The firm predicts the launch of Amvuttra, a transthyretin silencer for transthyretin amyloid cardiomyopathy, will see strong uptake in the first-line setting. Despite this, momentum for the drug’s launch is not expected until the second half of 2025.



Read more at Yahoo Finance: Alnylam price target raised to $338 from $300 at Scotiabank